Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena.Top-line results from the CLL14 ...

One of AbbVie’s most up-and-coming drugs faced a setback this week as the Food and Drug Administration placed a partial clinical hold on all the clinical trials testing it in a type of blood cancer.

Drug Overview Venclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell lymphoma-2 (BCL-2) family of proteins. This family of proteins is responsible for the regulation of cell death by ...

Venclexta represents a new treatment option for people with acute myeloid leukaemia regardless of subtypes Basel, 21 November 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US ...

Venclexta is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche group, in the US and commercialised by AbbVie outside of the US.

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena. Top-line results from the CLL14 ...